Login / Signup

Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence.

John P HaydekFrank I Scott
Published in: Alimentary pharmacology & therapeutics (2021)
Keyphrases
  • rheumatoid arthritis
  • ulcerative colitis
  • juvenile idiopathic arthritis
  • disease activity
  • hidradenitis suppurativa